ID

11850

Description

Epoetin Alfa Biosimilar in the Management of Chemotherapy-Induced Symptomatic Anemia in Haematology and Oncology; ODM derived from: https://clinicaltrials.gov/show/NCT02140736

Link

https://clinicaltrials.gov/show/NCT02140736

Keywords

Versions (1)
  1. 8/10/15 8/10/15 - Julian Varghese
Uploaded on

August 10, 2015

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Chemotherapy-induced Symptomatic Anemia NCT02140736

English

Eligibility Chemotherapy-induced Symptomatic Anemia NCT02140736

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

patients of more than 18 years of age
Description

patients of more than 18 years of age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
patients presenting with anemia following chemotherapy
Description

patients presenting with anemia following chemotherapy

Data type

boolean

Alias
UMLS CUI [1]
C3665472
UMLS CUI [2]
C0002871
patients suffer from solid tumours, malignant hemopathies, lymphomas or myelomas and presenting with anemia following chemotherapy
Description

patients suffer from solid tumours, malignant hemopathies, lymphomas or myelomas and presenting with anemia following chemotherapy

Data type

boolean

Alias
UMLS CUI [1]
C0280100
UMLS CUI [2]
C3665472
UMLS CUI [3]
C0376545
- the patients may be included regardless of their chemotherapy cycle (from the first cycle until the last cycle)
Description

- the patients may be included regardless of their chemotherapy cycle (from the first cycle until the last cycle)

Data type

boolean

patients eligible for epoetin alfa biosimilar treatment
Description

patients eligible for epoetin alfa biosimilar treatment

Data type

boolean

Alias
UMLS CUI [1,1]
C0013893
UMLS CUI [1,2]
C0357126
Exclusion Criteria
Description

Exclusion Criteria

patients are not receiving chemotherapy
Description

patients are not receiving chemotherapy

Data type

boolean

Alias
UMLS CUI [1]
C3665472
patients already included in an epoetin zeta trial
Description

patients already included in an epoetin zeta trial

Data type

boolean

Alias
UMLS CUI [1,1]
C2242969
UMLS CUI [1,2]
C1997870
patients presenting with a contraindication to epoetin zeta
Description

patients presenting with a contraindication to epoetin zeta

Data type

boolean

Alias
UMLS CUI [1,1]
C0522473
UMLS CUI [1,2]
C1997870
patients presenting with hypersensitivity to the active principle or any of the excipients
Description

patients presenting with hypersensitivity to the active principle or any of the excipients

Data type

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0014822
patient with erythroblastopenia or acquired pure red cell aplasia (aprca)
Description

patient with erythroblastopenia or acquired pure red cell aplasia (aprca)

Data type

boolean

Alias
UMLS CUI [1]
C0877221
UMLS CUI [2]
C0340961
patient with uncontrollable arterial hypertension
Description

patient with uncontrollable arterial hypertension

Data type

boolean

Alias
UMLS CUI [1]
C1868885
patients who cannot receive adequate prophylaxis by antithrombotic agents
Description

patients who cannot receive adequate prophylaxis by antithrombotic agents

Data type

boolean

Alias
UMLS CUI [1,1]
C0522473
UMLS CUI [1,2]
C1704311
Back to the top of the page

Similar models

Eligibility Chemotherapy-induced Symptomatic Anemia NCT02140736

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
age
Item
patients of more than 18 years of age
boolean
C0001779 (UMLS CUI [1])
Chemotherapy | Anemia | Hematologic Neoplasms
Item
patients presenting with anemia following chemotherapy
boolean
C3665472 (UMLS CUI [1])
C0002871 (UMLS CUI [2])
Solid tumour | Chemotherapy | Hematologic Neoplasms
Item
patients suffer from solid tumours, malignant hemopathies, lymphomas or myelomas and presenting with anemia following chemotherapy
boolean
C0280100 (UMLS CUI [1])
C3665472 (UMLS CUI [2])
C0376545 (UMLS CUI [3])
patient inclusion regardless of chemotherapy
Item
- the patients may be included regardless of their chemotherapy cycle (from the first cycle until the last cycle)
boolean
Eligibility Determination; Epoetin Alfa
Item
patients eligible for epoetin alfa biosimilar treatment
boolean
C0013893 (UMLS CUI [1,1])
C0357126 (UMLS CUI [1,2])
Chemotherapy
Item
patients are not receiving chemotherapy
boolean
C3665472 (UMLS CUI [1])
clinical trial participant (history); epoetin zeta
Item
patients already included in an epoetin zeta trial
boolean
C2242969 (UMLS CUI [1,1])
C1997870 (UMLS CUI [1,2])
Contraindication; epoetin zeta
Item
patients presenting with a contraindication to epoetin zeta
boolean
C0522473 (UMLS CUI [1,1])
C1997870 (UMLS CUI [1,2])
Hypersensitivity; Erythropoietin
Item
patients presenting with hypersensitivity to the active principle or any of the excipients
boolean
C0020517 (UMLS CUI [1,1])
C0014822 (UMLS CUI [1,2])
Decreased erythroid precursor production | Acquired red cell aplasia
Item
patient with erythroblastopenia or acquired pure red cell aplasia (aprca)
boolean
C0877221 (UMLS CUI [1])
C0340961 (UMLS CUI [2])
Uncontrolled hypertension
Item
patient with uncontrollable arterial hypertension
boolean
C1868885 (UMLS CUI [1])
Contraindication; Antithrombotic Agents
Item
patients who cannot receive adequate prophylaxis by antithrombotic agents
boolean
C0522473 (UMLS CUI [1,1])
C1704311 (UMLS CUI [1,2])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial